 MaxCyte Inc AIM:MXCT has again raised its full-year outlook as it continued to enjoy strong growth in the cell therapy market. Revenue came in at US9.6mln for the second quarter of 2022, up 35 year-on-year, with the core business growing 45 and drug discovery up 4. 